Heat Biologics (NASDAQ:HTBX) announced its quarterly earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.05), Bloomberg Earnings reports. The firm had revenue of $0.75 million during the quarter. Heat Biologics had a negative return on equity of 182.19% and a negative net margin of 543.30%.
Heat Biologics traded up $0.12, hitting $2.11, during midday trading on Wednesday, according to MarketBeat.com. 192,281 shares of the company traded hands, compared to its average volume of 4,216,315. Heat Biologics has a 52 week low of $1.09 and a 52 week high of $7.90.
Separately, ValuEngine upgraded shares of Heat Biologics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.